Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment

Overweight and obesity in youth is a worldwide public health problem. Overweight and obesity in childhood and adolescents have a substantial effect upon many systems, resulting in clinical conditions such as metabolic syndrome, early atherosclerosis, dyslipidemia, hypertension and type 2 diabetes (T2D). Obesity and the type of body fat distribution are still the core aspects of insulin resistance and seem to be the physiopathologic links common to metabolic syndrome, cardiovascular disease and T2D. The earlier the appearance of the clustering of risk factors and the higher the time of exposure, the greater will be the chance of developing coronary disease with a more severe endpoint. The age when the event may occur seems to be related to the presence and aggregation of risk factors throughout life

On the production of He, C, and N by low- and intermediate-mass stars: a comparison of observed and model-predicted planetary nebula abundances

The primary goal of this paper is to make a direct comparison between the measured and model-predicted abundances of He, C, and N in a sample of 35 well-observed Galactic planetary nebulae (PNe). All observations, data reductions, and abundance determinations were performed in house to ensure maximum homogeneity. Progenitor star masses (M ≤ 4M⊙) were inferred using two published sets of post-asymptotic giant branch model tracks and L and Teff values. We conclude the following: (1) the mean values of N/O across the progenitor mass range exceeds the solar value, indicating significant N enrichment in the majority of our objects; (2) the onset of hot bottom burning appears to begin around 2 M⊙, i.e. lower than ~5M⊙ implied by theory; (3) most of our objects show a clear He enrichment, as expected from dredge-up episodes; (4) the average sample C/O value is 1.23, consistent with the effects of third dredge up; and (5) model grids used to compare to observations successfully span the distribution over metallicity space of all C/O and many He/H data points but mostly fail to do so in the case of N/O. The evident enrichment of N in PN and the general discrepancy between the observed and model-predicted N/O abundance ratios signal the need for extra mixing as an effect of rotation and/or thermohaline mixing in the models. The unexpectedly high N enrichment that is implied here for low-mass stars, if confirmed, will likely impact our conclusions about the source of N in the Universe.Instituto de Astrofísica de La PlataFacultad de Ciencias Astronómicas y Geofísica

On the production of He, C, and N by low- and intermediate-mass stars: a comparison of observed and model-predicted planetary nebula abundances

The primary goal of this paper is to make a direct comparison between the measured and model-predicted abundances of He, C, and N in a sample of 35 well-observed Galactic planetary nebulae (PNe). All observations, data reductions, and abundance determinations were performed in house to ensure maximum homogeneity. Progenitor star masses (M ≤ 4M⊙) were inferred using two published sets of post-asymptotic giant branch model tracks and L and Teff values. We conclude the following: (1) the mean values of N/O across the progenitor mass range exceeds the solar value, indicating significant N enrichment in the majority of our objects; (2) the onset of hot bottom burning appears to begin around 2 M⊙, i.e. lower than ~5M⊙ implied by theory; (3) most of our objects show a clear He enrichment, as expected from dredge-up episodes; (4) the average sample C/O value is 1.23, consistent with the effects of third dredge up; and (5) model grids used to compare to observations successfully span the distribution over metallicity space of all C/O and many He/H data points but mostly fail to do so in the case of N/O. The evident enrichment of N in PN and the general discrepancy between the observed and model-predicted N/O abundance ratios signal the need for extra mixing as an effect of rotation and/or thermohaline mixing in the models. The unexpectedly high N enrichment that is implied here for low-mass stars, if confirmed, will likely impact our conclusions about the source of N in the Universe.Instituto de Astrofísica de La PlataFacultad de Ciencias Astronómicas y Geofísica

Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin

Abstract\ud \ud \ud \ud Background\ud \ud Apolipoprotein E (apoE) is a key component of the lipid metabolism. Polymorphisms at the apoE gene (APOE) have been associated with cardiovascular disease, lipid levels and lipid-lowering response to statins. We evaluated the effects on APOE expression of hypercholesterolemia, APOE ε2/ε3/ε4 genotypes and atorvastatin treatment in Brazilian individuals. The relationship of APOE genotypes and plasma lipids and atorvastatin response was also tested in this population.\ud \ud \ud \ud Methods\ud \ud APOE ε2/ε3/ε4 and plasma lipids were evaluated in 181 normolipidemic (NL) and 181 hypercholesterolemic (HC) subjects. HC individuals with indication for lowering-cholesterol treatment (n = 141) were treated with atorvastatin (10 mg/day/4-weeks). APOE genotypes and APOE mRNA in peripheral blood mononuclear cells (PBMC) were analyzed by TaqMan real time PCR.\ud \ud \ud \ud Results\ud \ud HC had lower APOE expression than NL group (p < 0.05) and individuals with low APOE expression showed higher plasma total and LDL cholesterol and apoB, as well as higher apoAI (p < 0.05). Individuals carrying ε2 allele have reduced risk for hypercholesterolemia (OR: 0.27, 95% I.C.: 0.08-0.85, p < 0.05) and NL ε2 carriers had lower total and LDL cholesterol and apoB levels, and higher HDL cholesterol than non-carriers (p < 0.05). APOE genotypes did not affect APOE expression and atorvastatin response. Atorvastatin treatment do not modify APOE expression, however those individuals without LDL cholesterol goal achievement after atorvastatin treatment according to the IV Brazilian Guidelines for Dyslipidemia and Atherosclerosis Prevention had lower APOE expression than patients with desirable response after the treatment (p < 0.05).\ud \ud \ud \ud Conclusions\ud \ud APOE expression in PBMC is modulated by hypercholesterolemia and the APOE mRNA level regulates the plasma lipid profile. Moreover the expression profile is not modulated neither by atorvastatin nor APOE genotypes. In our population, APOE ε2 allele confers protection against hypercholesterolemia and a less atherogenic lipid profile. Moreover, low APOE expression after treatment of patients with poor response suggests a possible role of APOE level in atorvastatin response.The present study was supported by a grant from FAPESP (Protocol # 2009/15125-8). We thank the volunteers for their participation and physicians and nurses from the Medical Clinics Division of the University Hospital of the University of Sao Paulo for technical support during patient selection. Alvaro Cerda is a recipient of a fellowship from CONICYT-Chile, Mario H. Hirata and Rosario D.C. Hirata were recipients from CNPq-Brazil, and Fabiana D.V. Genvigir, Maria A.V. Willrich and Simone S. Arazi were recipients from FAPESP-Brazil

Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin

Abstract\ud \ud Background\ud Apolipoprotein E (apoE) is a key component of the lipid metabolism. Polymorphisms at the apoE gene (APOE) have been associated with cardiovascular disease, lipid levels and lipid-lowering response to statins. We evaluated the effects on APOE expression of hypercholesterolemia, APOE ε2/ε3/ε4 genotypes and atorvastatin treatment in Brazilian individuals. The relationship of APOE genotypes and plasma lipids and atorvastatin response was also tested in this population.\ud \ud \ud Methods\ud APOE ε2/ε3/ε4 and plasma lipids were evaluated in 181 normolipidemic (NL) and 181 hypercholesterolemic (HC) subjects. HC individuals with indication for lowering-cholesterol treatment (n = 141) were treated with atorvastatin (10 mg/day/4-weeks). APOE genotypes and APOE mRNA in peripheral blood mononuclear cells (PBMC) were analyzed by TaqMan real time PCR.\ud \ud \ud Results\ud HC had lower APOE expression than NL group (p < 0.05) and individuals with low APOE expression showed higher plasma total and LDL cholesterol and apoB, as well as higher apoAI (p < 0.05). Individuals carrying ε2 allele have reduced risk for hypercholesterolemia (OR: 0.27, 95% I.C.: 0.08-0.85, p < 0.05) and NL ε2 carriers had lower total and LDL cholesterol and apoB levels, and higher HDL cholesterol than non-carriers (p < 0.05). APOE genotypes did not affect APOE expression and atorvastatin response. Atorvastatin treatment do not modify APOE expression, however those individuals without LDL cholesterol goal achievement after atorvastatin treatment according to the IV Brazilian Guidelines for Dyslipidemia and Atherosclerosis Prevention had lower APOE expression than patients with desirable response after the treatment (p < 0.05).\ud \ud \ud Conclusions\ud APOE expression in PBMC is modulated by hypercholesterolemia and the APOE mRNA level regulates the plasma lipid profile. Moreover the expression profile is not modulated neither by atorvastatin nor APOE genotypes. In our population, APOE ε2 allele confers protection against hypercholesterolemia and a less atherogenic lipid profile. Moreover, low APOE expression after treatment of patients with poor response suggests a possible role of APOE level in atorvastatin response

Weighing stars from birth to death : mass determination methods across the HRD

Funding: C.A., J.S.G.M., and M.G.P. received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 670519: MAMSIE). N.B. gratefully acknowledge financial support from the Royal Society (University Research Fellowships) and from the European Research Council (ERC-CoG-646928, Multi-Pop).The mass of a star is the most fundamental parameter for its structure, evolution, and final fate. It is particularly important for any kind of stellar archaeology and characterization of exoplanets. There exist a variety of methods in astronomy to estimate or determine it. In this review we present a significant number of such methods, beginning with the most direct and model-independent approach using detached eclipsing binaries. We then move to more indirect and model-dependent methods, such as the quite commonly used isochrone or stellar track fitting. The arrival of quantitative asteroseismology has opened a completely new approach to determine stellar masses and to complement and improve the accuracy of other methods. We include methods for different evolutionary stages, from the pre-main sequence to evolved (super)giants and final remnants. For all methods uncertainties and restrictions will be discussed. We provide lists of altogether more than 200 benchmark stars with relative mass accuracies between [0.3 ,2 ]% for the covered mass range of M ∈[0.1 ,16 ] M⊙ , 75 % of which are stars burning hydrogen in their core and the other 25 % covering all other evolved stages. We close with a recommendation how to combine various methods to arrive at a "mass-ladder" for stars.PostprintPeer reviewe

Weighing stars from birth to death: mass determination methods across the HRD

The mass of a star is the most fundamental parameter for its structure, evolution, and final fate. It is particularly important for any kind of stellar archaeology and characterization of exoplanets. There exists a variety of methods in astronomy to estimate or determine it. In this review we present a significant number of such methods, beginning with the most direct and model-independent approach using detached eclipsing binaries. We then move to more indirect and model-dependent methods, such as the quite commonly used isochrone or stellar track fitting. The arrival of quantitative asteroseismology has opened a completely new approach to determine stellar masses and to complement and improve the accuracy of other methods. We include methods for different evolutionary stages, from the pre-main sequence to evolved (super)giants and final remnants. For all methods uncertainties and restrictions will be discussed. We provide lists of altogether more than 200 benchmark stars with relative mass accuracies between $[0.3,2]\%$ for the covered mass range of M\in [0.1,16]\,\msun, $75\%$ of which are stars burning hydrogen in their core and the other $25\%$ covering all other evolved stages. We close with a recommendation how to combine various methods to arrive at a "mass-ladder" for stars.Comment: Invited review article for The Astronomy and Astrophysics Review. 146 pages, 16 figures, 11 tables. Accepted version by the Journal. It includes summary figure of accuracy/precision of methods for mass ranges and summary table for individual method

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response

Aims: The relationship between variants in SLCO1B1 and SLCO2B1 genes and lipid-lowering response to atorvastatin was investigated. Material and Methods: One-hundred-thirty-six unrelated individuals with hypercholesterolemia were selected and treated with atorvastatin (10 mg/day/4 weeks). They were genotyped with a panel of ancestry informative markers for individual African component of ancestry (ACA) estimation by SNaPshot® and SLCO1B1 (c.388A&gt;G, c.463C&gt;A and c.521T&gt;C) and SLCO2B1 (−71T&gt;C) gene polymorphisms were identified by TaqMan® Real-time PCR. Results: Subjects carrying SLCO1B1 c.388GG genotype exhibited significantly high low-density lipoprotein (LDL) cholesterol reduction relative to c.388AA+c.388AG carriers (41 vs. 37%, p = 0.034). Haplotype analysis revealed that homozygous of SLCO1B1*15 (c.521C and c.388G) variant had similar response to statin relative to heterozygous and non-carriers. A multivariate logistic regression analysis confirmed that c.388GG genotype was associated with higher LDL cholesterol reduction in the study population (OR: 3.2, CI95%:1.3–8.0, p &lt; 0.05). Conclusion: SLCO1B1 c.388A&gt;G polymorphism causes significant increase in atorvastatin response and may be an important marker for predicting efficacy of lipid-lowering therapy

Weighing stars from birth to death: mass determination methods across the HRD

The mass of a star is the most fundamental parameter for its structure, evolution, and final fate. It is particularly important for any kind of stellar archaeology and characterization of exoplanets. There exist a variety of methods in astronomy to estimate or determine it. In this review we present a significant number of such methods, beginning with the most direct and model-independent approach using detached eclipsing binaries. We then move to more indirect and model-dependent methods, such as the quite commonly used isochrone or stellar track fitting. The arrival of quantitative asteroseismology has opened a completely new approach to determine stellar masses and to complement and improve the accuracy of other methods. We include methods for different evolutionary stages, from the pre-main sequence to evolved (super)giants and final remnants. For all methods uncertainties and restrictions will be discussed. We provide lists of altogether more than 200 benchmark stars with relative mass accuracies between [0.3,2]% for the covered mass range of M∈[0.1,16]M⊙, 75% of which are stars burning hydrogen in their core and the other 25% covering all other evolved stages. We close with a recommendation how to combine various methods to arrive at a “mass-ladder” for stars.Instituto de Astrofísica de La Plat

Updated cardiovascular prevention guideline of the Brazilian Society of Cardiology: 2019

Sem informação113478788